medRxiv 预印本Codex · 实盘不做把握 2/10
北京时间·🕒 发布 07-23(UTC日)仅日期·时区推断·⟳ 抓取 16:09:23回填·⚡ 决策 07-27 16:15:22·92.3 天前
medRxiv预印本讨论C. difficile筛查方案并提及Cepheid Xpert检测
这是一篇医学预印本方法学研究，未披露医院采购、指南纳入、监管批准或商业订单。
📄 原文medRxiv 预印本↗ 原文
Optimized Surveillance Testing for Toxigenic Clostridioides difficile to Scale Prevention Programs Across Clinical Sett…
不做 丹纳赫（DHR.US）
医学预印本仅验证检测流程，未披露商业订单、指南纳入或监管批准；对丹纳赫短线收入和利润影响过小且不可量化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 medium ↗
关键理由
- 这是一篇医学预印本方法学研究，未披露医院采购、指南纳入、监管批准或商业订单。
- 文中Cepheid Xpert仅作为确认检测工具被使用，无法形成对丹纳赫（DHR.US）短周期收入或利润的可量化增量。
主要风险
- 预印本尚非临床指南或监管准入事件，即使科学结论为真，也难以转化为可交易催化。
原文全文
展开原文 · 1,243 字
Optimized Surveillance Testing for Toxigenic Clostridioides difficile to Scale Prevention Programs Across Clinical Settings
Clostridioides difficile is the leading cause of healthcare acquired infections (HAIs). Healthcare systems lack scalable strategies to identify patients colonized with toxigenic strains to inform prevention programs. We developed a scalable program using rectal swabs, collected for vancomycin resistance Enterococci surveillance, with ex vivo amplification of C. difficile in Cdiff Banana Broth (BB). Confirmatory testing of BB-positive tubes used the rapid C. difficile QuickCheck assay with Cepheid's Xpert(R) C. difficile/Epi (Xpert) to confirm toxin gene carriage for QuickCheck results that were C. difficile glutamate dehydrogenase-positive (GDH) and antigenic toxin-negative. BB with confirmation demonstrated 92% specificity and 100% sensitivity, to a limit of 6 months later. BB with confirmation provides a more sensitive method to detect patient colonization with toxigenic C. difficile and, by using VRE surveillance swabs, does not require additional patient samples. The simplified approach can be deployed across healthcare settings to support C. difficile-prevention programs.
主题词：infectious diseases
Clostridioides difficile is the leading cause of healthcare acquired infections (HAIs). Healthcare systems lack scalable strategies to identify patients colonized with toxigenic strains to inform prevention programs. We developed a scalable program using rectal swabs, collected for vancomycin resistance Enterococci surveillance, with ex vivo amplification of C. difficile in Cdiff Banana Broth (BB). Confirmatory testing of BB-positive tubes used the rapid C. difficile QuickCheck assay with Cepheid's Xpert(R) C. difficile/Epi (Xpert) to confirm toxin gene carriage for QuickCheck results that were C. difficile glutamate dehydrogenase-positive (GDH) and antigenic toxin-negative. BB with confirmation demonstrated 92% specificity and 100% sensitivity, to a limit of 6 months later. BB with confirmation provides a more sensitive method to detect patient colonization with toxigenic C. difficile and, by using VRE surveillance swabs, does not require additional patient samples. The simplified approach can be deployed across healthcare settings to support C. difficile-prevention programs.
主题词：infectious diseases
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。